Showing 11-20 of 25 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Innovation Partnership | LabCentral | Luke Wallrich | Cures | 07-July-2025 to 31-May-2026 | $200,000.00 |
| Effectiveness and safety of sotagliflozin in slowing kidney function decline in persons with type 1 diabetes and moderate to severe diabetic kidney disease: The SUGARNSALT Trial | Joslin Diabetes Center Inc. | Alessandro Doria | Improving Lives | 01-January-2024 to 31-December-2028 | $8,913,450.00 |
| Study of ALDH3B2 as a regulator of pancreatic beta cell neogenesis | Joslin Diabetes Center Inc. | Jian Li | Cures | 01-August-2023 to 31-July-2026 | $212,708.89 |
| Validation of a new approach for cardiovascular disease risk stratification and therapeutic targeting in T1D | Joslin Diabetes Center Inc. | Myra Lipes | Improving Lives | 01-September-2023 to 31-December-2025 | $966,378.00 |
| Harnessing insulin signaling in β-cells to counter type 1 diabetes | Joslin Diabetes Center Inc. | Namrata Shukla | Cures | 01-March-2024 to 28-February-2027 | $228,995.00 |
| Targeting RNLS for Type 1 Diabetes Therapy | Joslin Diabetes Center Inc. | Peng Yi | Cures | 01-June-2025 to 31-May-2028 | $1,349,997.00 |
| Evaluating the dose and toxicity of telaprevir in a rat model of T1D | Joslin Diabetes Center Inc. | Rohit Kulkarni | Cures | 01-June-2022 to 31-December-2025 | $494,000.00 |
| Advanced Oxygen Generator for Oxygenated Cell Capsules | Giner, Inc. | Linda Tempelman | Cures | 01-June-2021 to 31-December-2025 | $448,173.29 |
| Closing the T1D diagnosis gap in Ethiopia, Ghana and Nigeria | Clinton Health Access Initiative (CHAI) | Margaret Prust | Mission | 01-September-2023 to 31-August-2026 | $1,702,076.57 |
| T1D Global Access Grand Strategy | Clinton Health Access Initiative (CHAI) | Nine Steensma | Mission | 01-August-2024 to 30-September-2025 | $1,179,001.50 |